Skip to content

Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection

A Randomized Controlled Trial to Compare the Efficacy of Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03489070
Acronym
TSFHR
Enrollment
81
Registered
2018-04-05
Start date
2017-08-15
Completion date
2018-10-21
Last updated
2018-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Hemorrhage

Keywords

Liver resection, Liver Hemorrhage, Traumastem, Surgicel

Brief summary

Topical hemostats are agents that stop bleeding by contributing blood to clot. Oxidized cellulose, a sort of mechanical hemostatic material, predominantly forms a block to stop the blood flow and provides a surface to clot more rapidly.It was marketed for the first time in 1945 and widely used for its convenience, biocompatibility, and bactericide from that time. It is currently available in many commercial products, while manufactured using either a regenerated or nonregenerated process. The physicochemical property and hemostatic efficacy of oxidized regenerated cellulose (ORCG) and oxidized nonregenerated cellulose (ONRCG) has been well documented using in vitro test and animal models, and ONRCG was seemingly superior to ORCG in terms of hemostasis. However, no clinical study has been performed to verify. Therefore, the objective of this prospective randomized study is to assess the hemostatic efficacy of ORCG (Surgicel®, Ethicon) vs ONRCG (Traumastem®, Bioster) for hemostasis of local bleeding in patients undergoing hepatic resection.

Detailed description

Representative liver resected surface (prominent bleeding site) was applied the ply of gauze with several seconds of even finger gentle press under aseptic conditions, then it was untouched and observed for 10 min. Vascular occlusion of the liver was allowed if necessary, but was open for evaluation of hemostatic efficacy. Hemostatic time began to calculate when gauze was applied. Time to hemostasis was recorded in seconds and the maximum time to hemostasis was 600 seconds. Hemostasis success was achieved based on there was no visible bleeding or minimal ooze from the resection wound.

Interventions

COMBINATION_PRODUCTTraumastem®

Intraoperative application as secondary hemostatic treatment

COMBINATION_PRODUCTSurgicel®

Intraoperative application as secondary hemostatic treatment

Sponsors

China Medical University, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Inpatient with informed consent * Adults aged between 18 to 75 and do not plan to have child within 1 year after the surgery * Resection of at least the equivalent tissue volume of 1 anatomical segment of the liver * Minor to moderate (oozing/diffuse) bleeding from the incisal area after conventional resection procedure and primary control of arterial pulsating bleeding or major venous hemorrhage by sutures, ligations, vascular clips, or point electrocautery

Exclusion criteria

* Indication for emergency surgery * Participate in other clinical trials in the past 3 months * Obvious hematologic disorder (as judged by the investigator from anemia and coagulation dysfunction) * Patients with brain disease, abnormal judgment or mental disorder that does not cooperate with the researcher * Patients with asthma or allergies * Patients with severe cardiac disease, metabolic disease or endocrine disorders * Immunodeficient patients (AIDS) * Pregnancy, breastfeeding females * Skin infection in the field of the targeted incisional area

Design outcomes

Primary

MeasureTime frameDescription
Hemostatic time10 minutesHemostatic time began to calculate when gauze was applied.

Secondary

MeasureTime frameDescription
Postoperative drainage volumeIn the first day after surgeryDrainage volume through the site
Postoperative drainage timeUp time to removal of wound drain, an expected average of 1 weekThe duration of drainage
Hospital stayUp time to discharge from hospital,an expected average of 3 weeksTotal hospital stay
Postoperative hospital stayUp time to discharge from hospital,an expected average of 2 weeksTotal postoperative hospital stay

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026